Repair of primary RRD – comparing pars plana vitrectomy procedure with combined phacovitrectomy with standard foldable intraocular lens implantation

Figures & data

Table 1 Basic characteristics of study population

Patient and ophthalmic surgery related characteristics	VITRET, CKD92 group (n = 1,564), n (%)	PHACOVIT, CKD94 group (n = 126), n (%)	P-value
Sex			0.16
Male	1,034 (66.1)	75 (59.5)
Female	530 (33.9)	51 (40.5)
Age of the patient (years)			0.004
<40	56 (3.6)	6 (4.8)
40–<50	147 (9.4)	7 (5.5)
50–<60	482 (30.8)	23 (18.3)
≥60	879 (56.2)	90 (71.4)
Year of surgery			0.07
Before 2011	696 (44.5)	45 (35.7)
2011 or later	868 (55.5)	81 (64.3)
Statin therapy			0.66
No	1,273 (81.4)	100 (79.4)
Yes	291 (18.6)	26 (20.6)
Insulin use			0.99
No	1,520 (97.2)	122 (96.8)
Yes	44 (2.8)	4 (3.2)
OAD use			0.99
No	1,451 (92.8)	117 (92.9)
Yes	113 (7.2)	9 (7.1)
Antithrombotics			0.10
No	1,478 (94.5)	114 (90.5)
Yes	86 (5.5)	12 (9.5)
Beta-blockers			0.82
No	1,334 (85.3)	106 (84.1)
Yes	230 (14.7)	20 (15.9)
Duration of operation (h)			<0.0001
(0.3, <1.13)	584 (37.3)	19 (15.1)
(1.13, <1.5)	573 (36.6)	44 (34.9)
(1.5, 6.38)	407 (26.0)	63 (50.0)

Notes: P-value based on the chi-square test for independence. P ≤ 0.05 was considered as statistically significant. VITRET, CKD92, combined vitrectomy and retinal procedure; PHACOVIT, CKD94, combined phacoemulsification and IOL implantation together with PPV.

Abbreviations: OAD, oral antidiabetic drugs; IOL, intraocular lens; PPV, pars plana vitrectomy.

Table 2 Reoperation rate (per 100 person-years) with 95% CI

Operation type	Person-years (100)	Reoperations (n)	Rate + CI	IRR
CKD92	12.718	199	15.65 (13.55–17.98)	Reference
CKD94	0.791	33	41.73 (28.72–58.60)	2.67 (1.85–3.85)

Notes: VITRET, CKD92, combined vitrectomy and retinal procedure; PHACOVIT, CKD94, combined phacoemulsification and IOL implantation together with PPV. IRR from univariate Poisson model.

Abbreviations: CI, confidence interval; IRR, incidence rate ratio; IOL, intraocular lens; PPV, pars plana vitrectomy.

Figure 1 Survival from reoperation (N = 1,690) differed according to the surgical procedure (VITRET, CKD92 versus PHACOVIT, CKD94).

Notes: Kaplan-Meier curves with 95% CI. VITRET, CKD92, combined vitrectomy and retinal procedure; PHACOVIT, CKD94, combined phacoemulsification and IOL implantation together with PPV.
Abbreviations: CI, confidence interval; IOL, intraocular lens; PPV, pars plana vitrectomy.

Table 3 Diagnose codes for reoperations

Diagnosis for reoperation	VITRET, CKD92 group (n = 199)	PHACOVIT, CKD94 group (n = 33)
Retinal redetachment (H33.0)	149	24
Secondary pucker (H35.38)	28	2
Secondary MH (H35.37)	4	2
Exudative AMD (H33.1)	1	0
Vitreous hemorrhage (H43.1)	1	2
Mechanical complication of IOL (T85.2)	6	1
Secondary glaucoma (H40)	0	1
Complicated cataract (H26.2)	6	0
Suspected endophthalmitis (H44)	0	1
Secondary malignancy (C79.41)	1	0
No code	3	0

Notes: VITRET, CKD92, combined vitrectomy and retinal procedure; PHACOVIT, CKD94, combined phacoemulsification and IOL implantation together with PPV.

Abbreviations: ICD, International Classification of Diseases; MH, macular hole; AMD, age-related retinal degeneration; IOL, intraocular lens; PPV, pars plana vitrectomy.

Figure 2 Bayesian prediction of reoperation of RRD eyes according to eye procedure (VITRET, CKD92 versus PHACOVIT, CKD94), use of statin, use of insulin and use of oral diabetic treatment.

Note: VITRET, CKD92, combined vitrectomy and retinal procedure; PHACOVIT, CKD94, combined phacoemulsification and IOL implantation together with PPV.
Abbreviations: RRD, rhegmatogenous retinal detachment; IOL, intraocular lens; PPV, pars plana vitrectomy; GAD, oral antidiabetic drugs.